Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Mar 22, 2023 (4 years ago)

Alprazolam C-IV

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

Alprazolam C-IV, 0.5 mg, 30 Tabs per bottle, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534, NDC 72189-0240-30.

Affected NDC 72189-0240-30

Compare with the code on your package — it is the most precise check available.

Drug: Alprazolam Category: Mental Health Medication

Recalling firm
Direct Rx
NDC code
72189-0240-30
Origin
GA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0507-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Alprazolam recalls

See all
Class II · Moderate risk

Xanax XR

Failed Dissolution Specifications

Ongoing Dissolution failure Viatris, Inc. NDC 58151-506-91 D-0444-2026
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7596-3 D-0506-2023
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7595-3 D-0505-2023
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7594-3 D-0504-2023
Class II · Moderate risk

Alprazolam C-IV

CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.

Ongoing Cross-contamination Direct Rx NDC 72189-121-60 D-0509-2023

Other recalls by Direct Rx

All 2023 recalls
Class II · Moderate risk

Duloxetine D/R

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Direct Rx NDC 61919-482-30 D-0617-2026
Class II · Moderate risk

Duloxetine D/R

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Ongoing Nitrosamine impurity Direct Rx NDC 61919-0482-30 D-0568-2025
Class II · Moderate risk

Duloxetine D/R

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Ongoing Nitrosamine impurity Direct Rx NDC 61919-422-30 D-0567-2025
Class II · Moderate risk

Ciprofloxacin Ophth Solution

Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Ongoing Packaging defect Direct Rx NDC 61919-795-05 D-0364-2025